Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 92

1.

Obstructive sleep apnea in young infants with Down syndrome evaluated in a Down syndrome specialty clinic.

Goffinski A, Stanley MA, Shepherd N, Duvall N, Jenkinson SB, Davis C, Bull MJ, Roper RJ.

Am J Med Genet A. 2015 Feb;167A(2):324-30. doi: 10.1002/ajmg.a.36903. Epub 2015 Jan 13.

PMID:
25604659
2.

Abnormal mineralization of the Ts65Dn Down syndrome mouse appendicular skeleton begins during embryonic development in a Dyrk1a-independent manner.

Blazek JD, Malik AM, Tischbein M, Arbones ML, Moore CS, Roper RJ.

Mech Dev. 2015 May;136:133-42. doi: 10.1016/j.mod.2014.12.004. Epub 2014 Dec 30.

PMID:
25556111
3.

Raccoonpoxvirus safety in immunocompromised and pregnant mouse models.

Jones GJ, Boles C, Roper RL.

Vaccine. 2014 Jun 30;32(31):3977-81. doi: 10.1016/j.vaccine.2014.05.018. Epub 2014 May 14.

PMID:
24837508
4.
5.

Health information technology and hospital patient safety: a conceptual model to guide research.

Paez K, Roper RA, Andrews RM.

Jt Comm J Qual Patient Saf. 2013 Sep;39(9):415-25.

PMID:
24147353
6.

Non-trisomic homeobox gene expression during craniofacial development in the Ts65Dn mouse model of Down syndrome.

Billingsley CN, Allen JR, Baumann DD, Deitz SL, Blazek JD, Newbauer A, Darrah A, Long BC, Young B, Clement M, Doerge RW, Roper RJ.

Am J Med Genet A. 2013 Aug;161A(8):1866-74. doi: 10.1002/ajmg.a.36006. Epub 2013 Jul 10.

7.

Commonality in Down and fetal alcohol syndromes.

Solzak JP, Liang Y, Zhou FC, Roper RJ.

Birth Defects Res A Clin Mol Teratol. 2013 Apr;97(4):187-97. doi: 10.1002/bdra.23129. Epub 2013 Apr 3.

8.

A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer.

Paller CJ, Ye X, Wozniak PJ, Gillespie BK, Sieber PR, Greengold RH, Stockton BR, Hertzman BL, Efros MD, Roper RP, Liker HR, Carducci MA.

Prostate Cancer Prostatic Dis. 2013 Mar;16(1):50-5. doi: 10.1038/pcan.2012.20. Epub 2012 Jun 12.

9.

Antigen presentation assays to investigate uncharacterized immunoregulatory genes.

Roper RL.

Methods Mol Biol. 2012;890:259-71. doi: 10.1007/978-1-61779-876-4_15.

10.

Integrating intracellular dynamics using CompuCell3D and Bionetsolver: applications to multiscale modelling of cancer cell growth and invasion.

Andasari V, Roper RT, Swat MH, Chaplain MA.

PLoS One. 2012;7(3):e33726. doi: 10.1371/journal.pone.0033726. Epub 2012 Mar 26.

11.

Molecular characterization of the translocation breakpoints in the Down syndrome mouse model Ts65Dn.

Reinholdt LG, Ding Y, Gilbert GJ, Czechanski A, Solzak JP, Roper RJ, Johnson MT, Donahue LR, Lutz C, Davisson MT.

Mamm Genome. 2011 Dec;22(11-12):685-91. doi: 10.1007/s00335-011-9357-z. Epub 2011 Sep 28. Erratum in: Mamm Genome. 2011 Dec;22(11-12):692. Gilbert, Griffith T [corrected to Gilbert, Griffith J].

12.

Trisomic and allelic differences influence phenotypic variability during development of Down syndrome mice.

Deitz SL, Roper RJ.

Genetics. 2011 Dec;189(4):1487-95. doi: 10.1534/genetics.111.131391. Epub 2011 Sep 16.

13.

Deletion of the A35 gene from Modified Vaccinia Virus Ankara increases immunogenicity and isotype switching.

Rehm KE, Roper RL.

Vaccine. 2011 Apr 12;29(17):3276-83. doi: 10.1016/j.vaccine.2011.02.023. Epub 2011 Feb 23.

14.

Inferring gene regulatory networks from asynchronous microarray data with AIRnet.

Oviatt D, Clement M, Snell Q, Sundberg K, Lai CW, Allen J, Roper R.

BMC Genomics. 2010 Nov 2;11 Suppl 2:S6. doi: 10.1186/1471-2164-11-S2-S6.

15.

Disruption of bone development and homeostasis by trisomy in Ts65Dn Down syndrome mice.

Blazek JD, Gaddy A, Meyer R, Roper RJ, Li J.

Bone. 2011 Feb;48(2):275-80. doi: 10.1016/j.bone.2010.09.028. Epub 2010 Sep 24.

16.

Embryonic and not maternal trisomy causes developmental attenuation in the Ts65Dn mouse model for Down syndrome.

Blazek JD, Billingsley CN, Newbauer A, Roper RJ.

Dev Dyn. 2010 Jun;239(6):1645-53. doi: 10.1002/dvdy.22295.

17.

Effect of dutasteride on the risk of prostate cancer.

Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS; REDUCE Study Group.

N Engl J Med. 2010 Apr 1;362(13):1192-202. doi: 10.1056/NEJMoa0908127.

18.

Cellular signaling identifiability analysis: a case study.

Roper RT, Pia Saccomani M, Vicini P.

J Theor Biol. 2010 May 21;264(2):528-37. doi: 10.1016/j.jtbi.2010.02.029. Epub 2010 Feb 24.

PMID:
20188743
19.

PCR prescreen for genotyping the Ts65Dn mouse model of Down syndrome.

Lorenzi H, Duvall N, Cherry SM, Reeves RH, Roper RJ.

Biotechniques. 2010 Jan;48(1):35-8. No abstract available.

20.

Vaccinia virus decreases major histocompatibility complex (MHC) class II antigen presentation, T-cell priming, and peptide association with MHC class II.

Rehm KE, Connor RF, Jones GJ, Yimbu K, Mannie MD, Roper RL.

Immunology. 2009 Nov;128(3):381-92. doi: 10.1111/j.1365-2567.2009.03120.x.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk